FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2286199462> ?p ?o ?g. }

• W2286199462 endingPage "10009" @default.
• W2286199462 startingPage "10009" @default.
• W2286199462 abstract "10009 Background: Fenretinide (4-HPR), a cytotoxic retinoid, achieved limited and variable plasma levels when tested in a corn oil-based capsule. 4HPR/Lym-X-Sorb (LXS) oral powder is a new formulation intended to increase bioavailability, especially in children. Methods: This trial sought to define the toxicities, dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and pharmacokinetics of 4-HPR/LXS oral powder when given mixed in Slim-Fast nutritional shakes, twice a day for 7 days, every 21 days. Eligible patients had high-risk neuroblastoma with recurrent/progressive disease, or disease refractory or persistent after frontline therapy. Dose escalation was in 30% increments using the traditional 3 + 3 design. Plasma levels were measured by HPLC. Results: Thirty-two patients accrued to 8 Dose Levels (DL) (352 –2210 mg/m 2 /day); 30 patients were evaluable. No MTD was identified. There was a DLT elevation of alkaline phosphatase on DL1. No other DLT's were observed. Other toxicities included dry skin, elevated triglycerides, reversible nyctalopia, and transient transaminase elevation. Course 1 day 7 peak 4HPR plasma levels (Dose (mg/m2/day) - mean, (range)) were: 352 –6 μM (3.8–9.6); 458–11.5 μM (9.7–14.9); 595–17.6 μM (6–24.3); 774–15 μM (9.1–25.3); 1006–6.7 μM (5.2–9.2); 1308–13.9 μM (2.9–23.8); 1700–19.7 μM (17.3–24.3); and 2210–10.8 μM (4–16.5). Course 2 day 7 peak plasma levels trended higher than course 1 at DL5–8. Three patients with isolated bone marrow disease and one with MIBG avid bone lesions, had complete responses (DL4, DL4, DL7, DL8) receiving 10, 17, 18 and 10 courses of therapy, respectively. Six patients had stable disease for 4–27 courses (median 5.5) (DL3, DL4, DL4, DL5, DL6, DL8). Twenty patients had progressive disease. Central review of responses is pending. Conclusions: 4-HPR/LXS oral powder was well tolerated, obtained 2 - 5 fold higher 4HPR plasma levels than fenretinide capsules on the same dose and schedule (P < 0.01), and showed anti-tumor activity (complete responses in 4/15 patients at DL4–8). Based on pharmacokinetic data, a recommended Phase II dose and schedule is 1700 mg/m 2 /day × 7days every 3 weeks. No significant financial relationships to disclose." @default.
• W2286199462 created "2016-06-24" @default.
• W2286199462 creator A5005797590 @default.
• W2286199462 creator A5020759638 @default.
• W2286199462 creator A5025835928 @default.
• W2286199462 creator A5044056882 @default.
• W2286199462 creator A5054113399 @default.
• W2286199462 creator A5058354009 @default.
• W2286199462 creator A5064007701 @default.
• W2286199462 creator A5067387322 @default.
• W2286199462 creator A5077189142 @default.
• W2286199462 creator A5078499837 @default.
• W2286199462 date "2009-05-20" @default.
• W2286199462 modified "2023-10-01" @default.
• W2286199462 title "Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial" @default.
• W2286199462 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.10009" @default.
• W2286199462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27962534" @default.
• W2286199462 hasPublicationYear "2009" @default.
• W2286199462 type Work @default.
• W2286199462 sameAs 2286199462 @default.
• W2286199462 citedByCount "9" @default.
• W2286199462 countsByYear W22861994622012 @default.
• W2286199462 countsByYear W22861994622016 @default.
• W2286199462 crossrefType "journal-article" @default.
• W2286199462 hasAuthorship W2286199462A5005797590 @default.
• W2286199462 hasAuthorship W2286199462A5020759638 @default.
• W2286199462 hasAuthorship W2286199462A5025835928 @default.
• W2286199462 hasAuthorship W2286199462A5044056882 @default.
• W2286199462 hasAuthorship W2286199462A5054113399 @default.
• W2286199462 hasAuthorship W2286199462A5058354009 @default.
• W2286199462 hasAuthorship W2286199462A5064007701 @default.
• W2286199462 hasAuthorship W2286199462A5067387322 @default.
• W2286199462 hasAuthorship W2286199462A5077189142 @default.
• W2286199462 hasAuthorship W2286199462A5078499837 @default.
• W2286199462 hasConcept C104317684 @default.
• W2286199462 hasConcept C112705442 @default.
• W2286199462 hasConcept C126322002 @default.
• W2286199462 hasConcept C126894567 @default.
• W2286199462 hasConcept C181389837 @default.
• W2286199462 hasConcept C185592680 @default.
• W2286199462 hasConcept C2775954498 @default.
• W2286199462 hasConcept C2776715637 @default.
• W2286199462 hasConcept C2780533455 @default.
• W2286199462 hasConcept C2781121885 @default.
• W2286199462 hasConcept C29730261 @default.
• W2286199462 hasConcept C54355233 @default.
• W2286199462 hasConcept C55493867 @default.
• W2286199462 hasConcept C71924100 @default.
• W2286199462 hasConcept C81885089 @default.
• W2286199462 hasConcept C86803240 @default.
• W2286199462 hasConcept C90924648 @default.
• W2286199462 hasConcept C98274493 @default.
• W2286199462 hasConceptScore W2286199462C104317684 @default.
• W2286199462 hasConceptScore W2286199462C112705442 @default.
• W2286199462 hasConceptScore W2286199462C126322002 @default.
• W2286199462 hasConceptScore W2286199462C126894567 @default.
• W2286199462 hasConceptScore W2286199462C181389837 @default.
• W2286199462 hasConceptScore W2286199462C185592680 @default.
• W2286199462 hasConceptScore W2286199462C2775954498 @default.
• W2286199462 hasConceptScore W2286199462C2776715637 @default.
• W2286199462 hasConceptScore W2286199462C2780533455 @default.
• W2286199462 hasConceptScore W2286199462C2781121885 @default.
• W2286199462 hasConceptScore W2286199462C29730261 @default.
• W2286199462 hasConceptScore W2286199462C54355233 @default.
• W2286199462 hasConceptScore W2286199462C55493867 @default.
• W2286199462 hasConceptScore W2286199462C71924100 @default.
• W2286199462 hasConceptScore W2286199462C81885089 @default.
• W2286199462 hasConceptScore W2286199462C86803240 @default.
• W2286199462 hasConceptScore W2286199462C90924648 @default.
• W2286199462 hasConceptScore W2286199462C98274493 @default.
• W2286199462 hasIssue "15_suppl" @default.
• W2286199462 hasLocation W22861994621 @default.
• W2286199462 hasOpenAccess W2286199462 @default.
• W2286199462 hasPrimaryLocation W22861994621 @default.
• W2286199462 hasRelatedWork W16113689 @default.
• W2286199462 hasRelatedWork W1906504854 @default.
• W2286199462 hasRelatedWork W2014188853 @default.
• W2286199462 hasRelatedWork W2151172589 @default.
• W2286199462 hasRelatedWork W2349685912 @default.
• W2286199462 hasRelatedWork W2351351947 @default.
• W2286199462 hasRelatedWork W2375301095 @default.
• W2286199462 hasRelatedWork W2389091140 @default.
• W2286199462 hasRelatedWork W2406024219 @default.
• W2286199462 hasRelatedWork W2429954711 @default.
• W2286199462 hasVolume "27" @default.
• W2286199462 isParatext "false" @default.
• W2286199462 isRetracted "false" @default.
• W2286199462 magId "2286199462" @default.
• W2286199462 workType "article" @default.